Chromatics Color Sciences International. Inc; CCSI Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI

CCSI 29.32

+4.6%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jeffrey L. Henken who wrote (5599)	10/19/1999 9:43:00 AM
From: Jeffrey L. Henken	Read Replies (1) of 5736

Infant jaundice affects over half of all babies born and nearly 100% of all premature children. Every infant born is monitored for it. It is a liver-related disease and fundamentally occurs in varying degrees within the first two weeks of a child's life when the liver is trying to work on its own independent of the mother. If the liver doesn't take over quickly enough and the disease is not caught in time and then treated by phototherapy or exchange transfusion, the results can lie varying degrees of nervous system damage/or brain damage called Kernicterus. If left untreated, it is ultimately fatal. CCSI's Colormate TLc system is used to monitor infant jaundice. Every infant born is monitored. This market opportunity is huge.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next